The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy

Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt

  • Agoston Gyula Szabo
  • Jonathan Thorsen
  • Katrine Fladeland Iversen
  • Mette Bøegh Levring
  • Birgitte Preiss
  • Carsten Helleberg
  • Marie Fredslund Breinholt
  • Emil Hermansen
  • Gjerdrum, Lise Mette Rahbek
  • Søren Thorgaard Bønløkke
  • Katrine Nielsen
  • Eigil Kjeldsen
  • Elena Manuela Teodorescu
  • Marveh Dokhi
  • Eva Kurt
  • Casper Nørgaard Strandholdt
  • Mette Klarskov Andersen
  • Vangsted, Annette Juul
OriginalsprogEngelsk
TidsskriftAmerican Journal of Hematology
Vol/bind97
Udgave nummer3
Sider (fra-til)E117-E120
ISSN0361-8609
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
We thank the Department of Internal Medicine and the Hematological Clinical Research Unit at Vejle Hospital for providing the financial and logistical background for this study. Data management for this study was provided by Open Patient Exploratory Network, University of Southern Denmark.

Funding Information:
We thank the Department of Internal Medicine and the Hematological Clinical Research Unit at Vejle Hospital for providing the financial and logistical background for this study. Data management for this study was provided by Open Patient Exploratory Network, University of Southern Denmark.

ID: 313778617